Physician profile
Lien Diep
NPI 1528358181
$2,414.81
in general payments reported to CMS, 2019-2025
11 companies · $187 in 2025
The $187 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,734 · 2020: $57.56 · 2021: $11.17 · 2023: $245 · 2024: $180 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,828.41 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Teva Pharmaceuticals USA, INC. | $152.18 | 2019-2023 | Austedo Xr |
| Edwards Lifesciences Corporation | $117.42 | 2024 | Sapien 3 Ultra Resilia |
| Amylyx Pharmaceuticals, INC. | $89.70 | 2023 | Relyvrio |
| Argenx US, INC. | $72.50 | 2025 | Vyvgart |
| Alexion Pharmaceuticals, INC. | $62.31 | 2024 | |
| Sunovion Pharmaceuticals INC. | $30.53 | 2019-2020 | |
| Abbvie INC. | $21.81 | 2019 | |
| Abbott Laboratories | $17.09 | 2025 | Cardiomems |
| Acadia Pharmaceuticals INC | $11.69 | 2019 | |
| Kyowa Kirin, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lien Diep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.